Document Detail

Effects of alagebrium, an advanced glycation end-product breaker, in patients with chronic heart failure: study design and baseline characteristics of the BENEFICIAL trial.
MedLine Citation:
PMID:  20100811     Owner:  NLM     Status:  MEDLINE    
AIMS: Previous small open label studies have shown that the advanced glycation end-product (AGE) breaker alagebrium may improve cardiac function in patients with chronic heart failure (HF). We report the design, methods and baseline characteristics of a double-blind, placebo-controlled, randomized trial evaluating the efficacy and safety of alagebrium (BENEFICIAL) in patients with HF and a left ventricular ejection fraction (LVEF) <or= 0.45.
METHODS AND RESULTS: Patients with NYHA II-IV stable HF for at least 3 months were eligible for this study. One hundred and two patients were included in the study and randomized to either 200 mg alagebrium twice daily or placebo for a period of 36 weeks. The mean age of patients was 60 +/- 11 years, 78% were male, and 17% were diabetic. Mean peak VO(2) was 21.7 +/- 5.9 mL/min/kg, mean LVEF was 0.32 +/- 0.09. Diastolic function was worse (mean early tissue diastolic velocity (E') 4.6 +/- 1.7 vs. 6.1 +/- 2.0 cm/s; P < 0.001) in patients with LVEF <or= 0.35 compared to patients with LVEF between 0.35 and 0.45.
CONCLUSION: The BENEFICIAL study is a proof-of-concept study that will provide new data on the efficacy and safety of the AGE crosslink breaker alagebrium in systolic HF patients. EudraCT number of this trial is NCT00516646.
Suzan Willemsen; Jasper W L Hartog; Yoran M Hummel; Jan L Posma; Leen M van Wijk; Dirk J van Veldhuisen; Adriaan A Voors
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-01-25
Journal Detail:
Title:  European journal of heart failure     Volume:  12     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-16     Completed Date:  2010-06-10     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  294-300     Citation Subset:  IM    
Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Double-Blind Method
Echocardiography, Stress
Exercise Test
Exercise Tolerance
Glycosylation End Products, Advanced / antagonists & inhibitors*
Health Status Indicators
Heart Failure / drug therapy*,  ultrasonography
Middle Aged
Oxygen Consumption
Research Design
Stroke Volume
Thiazoles / therapeutic use*
Ventricular Function, Left
Reg. No./Substance:
0/Glycosylation End Products, Advanced; 0/Thiazoles; DGH49JXB1F/alagebrium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comment on analyzing addictive behaviors over time.
Next Document:  Rapid, nondenaturing RNA purification using weak anion-exchange fast performance liquid chromatograp...